Intravenous Iron Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Iron Dextran, Ferric Gluconate, Iron Sucrose, Ferric Carboxymaltos, Iron Isomaltoside 1000, Ferumoxytol), By Application (Intestinal Malabsorption Syndromes, Inflammatory Diseases, Gastrectomy/Bariatric Surgery, Anemia, Osier-Weber-Rendu Disease, Angiodysplasia, Pregnancy, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.55 Billion
CAGR (2026-2031)	5.77%
Fastest Growing Segment	Iron Dextran
Largest Market	North America
Market Size (2031)	USD 3.57 Billion

Market Overview

The Global Intravenous Iron Drugs Market is projected to grow from USD 2.55 Billion in 2025 to USD 3.57 Billion by 2031 at a 5.77% CAGR. Intravenous (IV) iron drugs are pharmaceutical formulations administered directly into the bloodstream to effectively treat iron deficiency and iron deficiency anemia, particularly in patients with intolerance or malabsorption of oral iron, or those requiring rapid iron repletion. The market's expansion is fundamentally driven by the increasing global prevalence of chronic kidney disease, inflammatory bowel disease, and various cancer-associated anemias. The aging global population, being more susceptible to iron deficiency conditions, further contributes to this demand. According to the World Health Organization's Global Anaemia estimates, 2025 Edition, in 2023, 30.7% of women aged 15-49 years suffered from anaemia, highlighting a significant underlying patient pool.

However, a notable challenge impeding market growth is the high cost associated with developing and manufacturing these advanced intravenous therapies, potentially limiting their widespread adoption in diverse healthcare systems.

Key Market Drivers

The inherent limitations and intolerance associated with oral iron therapies serve as a primary driver for the global intravenous iron drugs market. Many patients experience gastrointestinal side effects, leading to poor adherence or discontinuation. Moreover, conditions like inflammatory bowel disease, chronic kidney disease, and bariatric surgery often impede oral iron absorption, making it ineffective. The critical need for rapid iron repletion in acute settings or for severe anemia further necessitates intravenous administration. For instance, according to the American Society of Hematology (ASH) Annual Meeting and Exposition, in December 2025, a multidisciplinary project led to a 20-fold rise in intravenous iron infusions for pregnant patients within a year, demonstrating a clear preference for efficient treatment where oral options fall short.

Concurrently, advancements in intravenous iron formulations are significantly expanding the market by offering improved safety profiles, faster infusion times, and enhanced patient convenience. Pharmaceutical companies are actively developing next-generation products with optimized pharmacokinetics and reduced immunogenic potential, enabling higher single doses and fewer administrations. These innovations address historical challenges such as hypersensitivity reactions and prolonged infusion durations. For example, according to CSL's 2025 Annual Report, released in August 2025, CSL Vifor was preparing for over 30 planned product launches across its iron and nephrology portfolios, reflecting substantial pipeline development. This focus on improved formulations is crucial given the persistent burden of iron deficiency; according to the World Health Organization's Global Anaemia estimates, 2025 Edition, in 2023, 35.5% of pregnant women aged 15-49 years suffered from anaemia.

Download Free Sample Report

Key Market Challenges

The high cost associated with developing and manufacturing advanced intravenous iron therapies presents a significant challenging factor impeding the growth of the global intravenous iron drugs market. These sophisticated formulations necessitate substantial investment throughout their lifecycle, from initial research and extensive clinical trials to specialized production processes and stringent regulatory approvals. This considerable financial outlay directly translates into elevated product pricing in the market.

This elevated pricing limits the widespread adoption of intravenous iron drugs, particularly within healthcare systems characterized by budget constraints or restrictive reimbursement policies. According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), global pharmaceutical research and development expenditure is projected to exceed USD 200 billion in 2025, illustrating the substantial financial commitments within the industry that influence final drug costs. Consequently, access to these essential treatments becomes restricted for a considerable patient population, directly hampering the overall expansion of the market, despite the increasing global prevalence of iron deficiency conditions and related anemias.

Key Market Trends

The global intravenous iron drugs market is undergoing a notable shift toward outpatient and home-based administration. This trend is driven by increasing patient preference for convenience, reduced hospital visits, and the potential for lower healthcare costs associated with decentralized care settings. Advancements in portable infusion devices and the development of formulations allowing for faster and higher single-dose infusions further facilitate this transition, enabling more patients to receive necessary iron repletion outside traditional hospital environments.

Concurrently, the growing market penetration of biosimilars and cost-effective generic intravenous iron formulations represents another significant trend. The introduction of these alternatives intensifies competition, leading to downward pressure on drug pricing and expanded access to therapy for a wider patient population. For instance, CSL, a major player in the market, reported asset impairments totaling $1.1 billion for its 2026 fiscal year, partly attributed to increased generic competition for its iron replacement therapy Venofer, as highlighted by Fierce Pharma in February 2026. This competition is crucial for healthcare systems aiming to manage pharmaceutical expenditure while ensuring essential treatments remain accessible.

Segmental Insights

In the Global Intravenous Iron Drugs Market, Iron Dextran represents a significant and growing segment due to its established efficacy and advantageous administration profile. It is particularly valued for treating iron deficiency anemia in patients who are intolerant to oral iron therapy or have shown an inadequate response. The ability of Iron Dextran to deliver a substantial iron dose in a single infusion often reduces the need for multiple patient visits, enhancing treatment adherence and convenience. Furthermore, its approval by regulatory bodies such as the US Food and Drug Administration (FDA) reinforces its credibility and broadens its clinical application for appropriate patient populations.

Regional Insights

North America leads the global intravenous iron drugs market, primarily driven by a substantial prevalence of chronic conditions such as chronic kidney disease, cancer, and inflammatory bowel disease, which significantly contribute to iron deficiency anemia. The region benefits from a highly developed healthcare infrastructure, encompassing advanced outpatient infusion services and dialysis clinics that support widespread adoption of intravenous iron therapies. Furthermore, a supportive regulatory framework, exemplified by the U.S. Food and Drug Administration approvals, alongside comprehensive reimbursement systems like Medicare and Medicaid, ensures favorable market access and utilization of these essential drugs. This robust environment facilitates continuous innovation and product availability, solidifying North America's market dominance.

Recent Developments

• In November 2025, AFT Pharmaceuticals reported positive Phase III clinical trial results for its novel intravenous iron development project. The study indicated that the new medicine offered potential patient benefits, demonstrating better tolerability and fewer side effects compared to the leading intravenous iron product currently available. This breakthrough research aims to target a substantial market for intravenous iron treatments. The company confirmed its preparations to launch a subsequent large-scale study, which is crucial for supporting global regulatory approval of this innovative iron therapy.
• In October 2025, ACA Pharma and Azurity Pharmaceuticals announced an exclusive distribution partnership. Under this agreement, ACA Pharma gained commercialization rights for Feraheme® (ferumoxytol injection) across key Asian markets, including Hong Kong, Macau, the Greater Bay Area, Mainland China, and Singapore. Feraheme is an intravenous iron replacement therapy used for adult patients with iron deficiency anemia who are intolerant or unresponsive to oral iron, or who have chronic kidney disease. This collaboration aims to address the widespread prevalence of anemia in these regions by expanding access to an important intravenous iron treatment.
• In September 2025, Sandoz, a global leader in affordable medicines, initiated the U.S. launch of its generic iron sucrose injection. This followed recent approval by the U.S. Food and Drug Administration (FDA) for the treatment of iron deficiency anemia in patients with chronic kidney disease. The introduction of this injectable therapy expanded Sandoz's portfolio of iron treatments in the American market, reinforcing its commitment to providing more accessible medicines for chronic conditions. This product is a cornerstone therapy for millions of U.S. patients affected by iron deficiency anemia, particularly those with chronic kidney disease.
• In August 2025, Viatris Inc., a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) had approved its Iron Sucrose Injection, USP. This intravenous iron replacement product is indicated for treating iron deficiency anemia (IDA) in adult and pediatric patients (two years of age and older) who suffer from chronic kidney disease (CKD). The approval represented a significant advancement for patients with this condition and highlighted Viatris's capabilities in developing complex generic medicines. The generic version of Venofer® Injection was expected to become available shortly after its approval in various single-dose vial strengths, contributing to enhanced treatment access.

Key Market Players

• AMAG pharmaceuticals, Inc.
• Vifor Pharma Management Ltd.
• Daiichi Sankyo Company, Limited
• Rockwell Medical Inc.
• Allergan PLC
• Pfizer Inc.
• Nippon Shinyaku Co.
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Bausch Health Companies Inc.

By Product	By Application	By Region
Iron Dextran Ferric Gluconate Iron Sucrose Ferric Carboxymaltos Iron Isomaltoside 1000 Ferumoxytol	Intestinal Malabsorption Syndromes Inflammatory Diseases Gastrectomy/Bariatric Surgery Anemia Osier-Weber-Rendu Disease Angiodysplasia Pregnancy Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Intravenous Iron Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Intravenous Iron Drugs Market, By Product:

• Iron Dextran
• Ferric Gluconate
• Iron Sucrose
• Ferric Carboxymaltos
• Iron Isomaltoside 1000
• Ferumoxytol

• Intravenous Iron Drugs Market, By Application:

• Intestinal Malabsorption Syndromes
• Inflammatory Diseases
• Gastrectomy/Bariatric Surgery
• Anemia
• Osier-Weber-Rendu Disease
• Angiodysplasia
• Pregnancy
• Others

• Intravenous Iron Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE